Primary Thrombotic Microangiopathy in Pediatric Patients

Background . Primary thrombotic microangiopathy includes hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli , atypical hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Methodology . A retrospective study that included patients younger than 18 years diagnose...

Full description

Saved in:
Bibliographic Details
Main Authors: Andrés David Aranzazu Ceballos MD, Lina María Martínez Sánchez MSc, Ana Paulina Pamplona Sierra MD, Daniela Vergara Yánez MD, Liliana Franco Hincapié PhD, Richard Baquero Rodriguez MD
Format: Article
Language:English
Published: SAGE Publishing 2024-12-01
Series:Global Pediatric Health
Online Access:https://doi.org/10.1177/2333794X241307535
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background . Primary thrombotic microangiopathy includes hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli , atypical hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Methodology . A retrospective study that included patients younger than 18 years diagnosed with primary thrombotic microangiopathy between 2011 and 2021. Results . Thirty patients were included, of which 63% corresponded to a hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli , and 30% to the atypical hemolytic uremic syndrome. The median age was 2.8 years and female sex predominated at 57%. On admission to the emergency room, fever and fatigue were the most frequent symptoms (93%), followed by oliguria and anuria (80%). 48% of patients received hemodialysis during their care. Mortality was estimated at 13%. Conclusion . This study constitutes the largest series of primary thrombotic microangiopathy in the pediatric population of Latin America, where the etiological and clinical behavior of this condition is described.
ISSN:2333-794X